Dr. Axe Wire · Study decoded · health

Milk Protein Peptide Eases Blood Sugar Problems In Diabetic Mice

A dairy protein fragment calmed blood sugar swings and inflammation in diabetic mice, pointing to a possible food-based tool for blood sugar support.

By Dr. Axe Editorial Team · October 27, 2026 · 1 source · Watch

Photo: Pexels

A peptide derived from casein, milk's main protein, improved blood sugar control and insulin sensitivity in diabetic mice, according to a study published October 19, 2026 in Food & Function.

Researchers at Chinese institutions analyzed a casein-derived peptide mixture, made of protein fragments under 3,000 daltons, using mass spectrometry that identified 880 distinct peptides. Among the 50 most abundant, all were predicted to block DPP-IV, an enzyme that breaks down hormones involved in blood sugar control; 26 were predicted to block alpha-glucosidase, and one to block alpha-amylase, both involved in carbohydrate digestion. In lab testing, the mixture inhibited DPP-IV in a dose-dependent way, with 5.06 milligrams per milliliter needed to block the enzyme by half. The peptides crossed human intestinal cells in a dish partly via the PepT1 transport protein. In mice with diet- and chemically-induced type 2 diabetes, the mixture improved glucose tolerance and insulin sensitivity, eased unhealthy blood fats, reduced tissue injury and inflammation, and restored GLP-1/DPP-IV balance and IRS1/PI3K/AKT insulin-signaling.

DPP-IV inhibitors are an established drug strategy for type 2 diabetes, since blocking that enzyme preserves more natural GLP-1, the hormone that helps release insulin after meals. The authors propose this casein peptide works through a similar mechanism, plus effects on insulin-signaling and gut absorption, giving food-derived peptides a plausible rationale as a blood sugar support strategy distinct from existing DPP-IV drugs.

DPP-IV Half-Inhibition Concentration

Food & Function, 2026, Liang et al.

This mouse study used a purified, concentrated extract, not a consumer food or supplement, so human effects from eating dairy or taking a casein supplement are unknown. The mice had induced diabetes rather than naturally occurring disease, and no human trial, dose, or safety data were reported. Human studies, including dose and safety, are the logical next step.

Dr. Axe’s Take

A dairy-derived peptide hitting the same gut hormone system GLP-1 drugs target is a plausible mechanism, not a finished product; I wouldn't tell someone to drink more milk based on this mouse study using a lab-purified extract. For anyone on a GLP-1-class medicine, I pair these medicines with a whole-food diet, high protein, fiber and resistance training, since those protect muscle and support similar insulin pathways. Many people do well on a much lower dose, often 10 to 20% of labeled dose, worked out with the prescribing doctor rather than adjusting yourself. Watch for muscle loss and regain after stopping.

— Dr. Axe

Take the Metabolic Health Quiz →

Study summary

Who: HFD/STZ-induced type 2 diabetic mice; human intestinal cell line (Caco-2) used for transport testing
Design: Peptide profiling via LC-MS/MS, in vitro enzyme inhibition assays, and in vivo testing in a diabetic mouse model
Dose: Casein peptide extract (under 3 kDa); DPP-IV half-inhibition at 5.06 ± 0.41 mg/mL in vitro
Primary result: Casein peptide mixture improved glucose tolerance and insulin sensitivity in diabetic mice
Secondary: 880 peptides identified; all top 50 predicted to inhibit DPP-IV, 26 predicted to inhibit alpha-glucosidase; reduced dyslipidemia, tissue injury and inflammation; restored GLP-1/DPP-IV balance and IRS1/PI3K/AKT signaling
Funding / conflicts: Funder listed in the journal record: National Key Research and Development Program of China. Conflicts not reported in the abstract.
Date: Oct 19, 2026